The mammalian target of rapamycin (mTOR) is a serine/ threonine kinase that controls many aspects of cellular physiology, including transcription, translation, cell size, cytoskeletal organization and autophagy. Recent advances in the mTOR signaling field have found that mTOR exists in two heteromeric complexes, mTORC1 and mTORC2. The activity of mTORC1 is regulated by the integration of many signals, including growth factors, insulin, nutrients, energy availability and cellular stressors such as hypoxia, osmotic stress, reactive oxygen species and viral infection. In this review we highlight recent advances in the mTOR signaling field that relate to how the two mTOR complexes are regulated, and we discuss stress conditions linked to the mTOR signaling network that have not been extensively covered in other reviews. Given the diversity of signals that have been shown to impinge on mTOR, we also speculate on other signaltransduction pathways that may be linked to mTOR in the future.
Introduction
'You may trod me in the very dirt. But still, like dust, I'll arise. ' -Maya Angelou
The story of the drug rapamycin and its cellular target TOR is one that literally grew from the ground. Rapamycin was first isolated from soil samples on the South Pacific island of Rapa Nui, and surprisingly, the drug was subsequently found to have significant immunosuppressive and anti-tumor properties. Rapamycin targets a protein aptly named TOR, for 'target of rapamycin,' which is a serine/threonine kinase that is robustly regulated by a diverse array of upstream signals. Over the past 10 years, a considerable amount of work has been dedicated to elucidating the upstream regulation of the TOR protein in vivo. This work has been greatly facilitated by the exquisite specificity of rapamycin for TOR, the conservation of components of the TOR signaling network from yeast to man, and the significant biological phenotypes that are mediated by TOR kinase activity. TOR is compelling to study not only because it is the target of the drug rapamycin, but also because mammalian TOR (mTOR) is dysregulated in an array of human malignancies, metabolic disorders such as type II diabetes and a subset of benign tumor syndromes for which mTOR-inhibiting drugs such as rapamycin have begun to show great promise Manning, 2004) . Moreover, the signaling networks that lead to TOR are compelling to study because TOR regulates a vast range of cellular activities, including: transcription, translation, cell size, mRNA turnover, protein stability, ribosomal biogenesis, autophagy, long-term neural potentiation, vesicular trafficking and cytoskeletal organization (for reviews on the downstream regulation of TOR, see Fingar and Blenis (2004) ; Hay and Sonenberg (2004) ; Martin and Hall (2005) ). TOR also regulates itself through both negative and positive feedback mechanisms . Undoubtedly the best described function of mammalian TOR is its regulation of translation, and one mechanism by which mTOR regulates translation is by directly phosphorylating the key translation regulators p70 ribosomal S6 kinase (S6K) and eukaryotic initiation factor 4E binding protein 1 (4EBP1) (Figure 1 ). Under basal conditions, S6K and 4EBP1 are bound to a scaffolding protein, the eukaryotic initiation factor 3 (eIF3) translation initiation complex; but upon stimulation, mTOR phosphorylates and activates S6K and 4EBP1, causing their dissociation from eIF3 (Holz et al., 2005) . The phosphorylation of S6K on T389 and 4EBP1 on T37 and T41 are often used as functional readouts of mTOR activity, since these sites are specifically phosphorylated by mTOR both in vitro and in vivo and are inhibited by rapamycin treatment (Brown et al., 1995; Brunn et al., 1997) . After activation by mTOR, S6K phosphorylates the ribosomal protein S6, leading to an increase in translation of a subset of mRNAs. Originally it was thought that S6K enhanced the translation of mRNAs that contained specific, repetitive 5 0 -terminal oligopolypyrimidine (5 0 TOP) tracts; but more recently it has been suggested that mTOR regulates 5 0 TOP mRNAs independently of S6K (Stolovich et al., 2002) . mTOR also phosphorylates 4EBP1, and in doing so it inhibits 4EBP1 function. The net result of this action is to increase the translation of mRNAs with 7-methyl guanine caps, as 4EBP1 is an inhibitor of the capdependent initiation factor eIF4E. It is especially significant that mTOR leads to enhancement of translation through S6K, 4EBP1 and other molecules, since it has been postulated that mTOR may serve as a nexus that controls up to 15% of the bulk translation of the cell (Jefferies et al., 1994) . Moreover, translation regulation -especially through eIF4E -directly increases the size (and hence the growth) of cells via regulation of key growth promoting proteins such as c-Myc and cyclin D1 (Mamane et al., 2004) .
Although the regulation of transcription by major cellular signaling pathways has been extensively studied owing to the widespread use of microarray analysis, the study of the regulation of translation is far behind; and the relative contribution of translation versus transcription in modulating cellular phenotypes is only beginning to be studied (reviewed by Prendergast (2003) ; Rajasekhar and Holland (2004) ; Mata et al. (2005) ). For example, one pioneering report showed that the immediate effect of overexpressing the Ras and Akt oncogenes in glial progenitor cells was not to change mRNA transcription, but rather to increase the translation of specific growthand translation-promoting mRNAs (Rajasekhar et al., 2003) . Since mTOR serves as an integration point that relays numerous upstream signals to the translation apparatus, it is essential to appreciate how it is regulated. Figure 1 A model illustrating how mTOR fits within the insulin/Akt signaling network. Insulin or insulin-like growth factor initiates signaling at the insulin receptor, leading to activation of IRS1 and PI3K. The lipid products of PI3K, PIP3 (i.e. phosphatidylinositol 3,4,5 trisphosphate and phosphatidylinositol 3,4 bisphosphate), recruit both PDK1 and Akt to the plasma membrane. Akt is subsequently phosphorylated on T308 by PDK1 and by mTORC2 (consisting of mTOR, mLST8 and Rictor) on S473, leading to full activation. Akt then phosphorylates numerous targets to promote growth and survival, including the TSC1/2 complex. By phosphorylating TSC2, Akt inactivates TSC2s GAP activity for the small G protein Rheb. GTP-bound Rheb is a potent activator of the rapamycin-sensitive complex mTORC1 (consisting of mTOR, mLST8 and Raptor), but it is unclear whether Rheb plays a role in regulating mTORC2. mTORC1 phosphorylates several targets, including the translation control proteins S6K and 4EBP1. By phosphorylating and activating S6K, mTORC1 initiates a negative feedback loop to modulate its own activity, via S6K-mediated reduction in the activation of PI 3-kinase.
In this review, we focus on the upstream regulation of mTOR, outlining several of the major agonists and antagonists that have been shown to impinge upon the mTOR signaling network in mammalian cells (Table 1) . There is a great body of work describing TOR signaling in both fly and yeast model systems that serves as the bedrock of mammalian TOR research; and although we cannot do justice to the depth and breadth of this work, we will discuss significant similarities and differences in evolutionary conservation. We will also briefly discuss how mTOR exists in two complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) and how the existence of mTOR in these two distinct complexes has implications for upstream regulation. Furthermore, we speculate that as signaling pathways and cellular biological phenotypes often require translation, mTOR's role as a key regulator of translation (and other aspects of cellular physiology) may mean that many other signaling pathways will be tied to mTOR in the future.
mTORC1 and mTORC2
mTOR (also known as FRAP and RAFT) is a B289 kDa member of the phosphatidylinositol 3-kinase related kinase (PIKK) family of kinases, but it is exclusively a protein kinase. It exists in a large multiprotein complex, approximately 1.5-2 MDa in size when purified by gel filtration chromatography (Kim et al., 2002; Bader and Vogt, 2004) . Despite the fact that there are few well-characterized mTOR-interacting proteins, the domain architecture of mTOR suggests the existence of significant protein-protein interaction. From N-to C-terminus, mTOR contains: 20 HEAT repeats, which are protein-protein interaction domains consisting of two tandem a-helicies that are also found in the DNA damage-sensing kinases Rad3-related kinase ATR and ataxia-telangiectasia mutated (ATM) (Perry and Kleckner, 2003) ; a focal adhesion targeting (FAT) domain, found in all PIKK family members (Bosotti et al., 2000) ; an FRB domain, which binds the (Chiu et al., 1994) ; the kinase domain; and a focal adhesion targeting C-terminal domain (FATC), which is a second FAT domain at the C-terminus. As mTOR is such a large molecule it is possible that other functional domains that are not obvious from its primary sequence will be identified in the future.
In the yeast Saccharomyces cerevisiae, there are two TOR genes, TOR1 and TOR2, which share several functions, including translation, ribosome biogenesis, amino-acid transport and autophagy. Unlike TOR1, TOR2 has certain functions that cannot be inhibited by rapamycin, including the unique function of actin cytoskeleton regulation (Loewith et al., 2002; Jacinto et al., 2004) . The two TOR complexes in yeast, TORC1 and TORC2, have been purified; and the mammalian homologs of the TORC1 and TORC2 proteins that are conserved between yeast and mammals have also been discovered. As in yeast, there are two functionally distinct TOR complexes in mammals, mTORC1 and mTORC2; but unlike yeast, there is only one mTOR protein ( Figure 1 ).
It is critical to note that mTORC1 is the only known target of the drug rapamycin. Before binding mTOR, rapamycin must first complex with another molecule, the 12-kDa immunopilin FKBP12; and the rapamycin-FKBP12 complex (but not the FK506-FKBP12 complex) inhibits mTORC1 directly and potently (Brown et al., 1994; Chiu et al., 1994; Sabatini et al., 1994; Sabers et al., 1995) . It is unclear how the rapamycin-FKBP12 complex is excluded from mTORC2, but the recent discovery of several components of mTORC1 and mTORC2 will be of great value in answering this question. mTORC1 has recently been shown to consist of the three proteins mTOR, mLST8 (also known as GbL) and Raptor (for regulatory associated protein of mTOR), and largely controls translation and cell growth in response to nutrients. mTORC2 consists of mTOR, mLST8 and Rictor (for rapamycin-insensitive companion of mTOR), and has been shown to control actin cytoskeleton dynamics Sarbassov et al., 2004) . The mTORC1 component Raptor binds mTOR, S6K and 4EBP1, and facilitates mTOR phosphorylation of these molecules; but whether raptor enhances or represses mTOR kinase activity remains unclear (Hara et al., 2002; Kim et al., 2002) . As is the case in yeast, mTORC2 is decidedly rapamycin insensitive, and the protein Rictor dictates the specificity of mTORC2 towards Akt (discussed below) and away from S6K and 4EBP1 . The adaptor protein mLST8 is common to both complexes. It has been shown to both increase the kinase activity of mTORC1 towards S6K and 4EBP1 , and it also plays a positive role in mTORC2 function in cell spreading and actin polymerization (Jacinto et al., 2004) . Over the past 10 years, a great deal of work involving mTOR has focused on the use of rapamycin to modulate mTOR, and S6K and 4EBP1 phosphorylation have often been used as readouts for mTOR activity; therefore, mTORC1 has been the most extensively studied mTOR complex. Much less is known about the upstream regulation and function of mTORC2 than is known for mTORC1, although such work will undoubtedly be an active area of future investigation. Unless specifically mentioned, instances where 'mTOR' is mentioned throughout this review will refer to mTORC1.
Insulin and growth factor signaling to mTOR Directly upstream of mTOR: TSC1/2 and Rheb A renaissance in the mTOR field occurred upon the discovery that the tuberous sclerosis complex (TSC) gene products, TSC1 and TSC2, act upstream of mTOR. Tsc1 and tsc2 are tumor suppressor genes that are mutated in the disease TSC, a dominantly inherited disorder characterized by the formation of a distinguishing type of benign tumor -termed hamartoma -in many organ systems. The proteins TSC1 and TSC2 form a tight complex in the cell, and the presence of both proteins is required for the TSC1/2 heterodimer to function. Cells null for TSC1 or TSC2, cells depleted of TSC1 or TSC2 by RNA interference (RNAi), and human and mouse tissues deficient in TSC1 or TSC2, all have high mTORC1 activity, as measured by S6K and 4EBP1 phosphorylation (Gao et al., 2002; Goncharova et al., 2002; Inoki et al., 2002; Potter et al., 2002) . The discovery of the TSC1/2 complex as an important negative regulator of mTOR is a striking example of how mammalian biochemistry can complement Drosophila genetics. TSC1's and TSC2's role in cell growth was originally discovered through a genetic screen in Drosophila for genes, that when mutated, produced overgrown cells and organs. The observation that TSC1 and TSC2 were two such genes, and the epistatic analysis that placed them between growth factor signals and S6K (Gao and Pan, 2001; Potter et al., 2001; Tapon et al., 2001) , ultimately led to the overexpression and downregulation experiments in mammalian cells that established that TSC1 and TSC2 act upstream of mTOR.
A key function of TSC2 is that of a guanine triphosphate (GTP)ase activating protein (GAP) for a small G protein named Rheb (for Ras homolog enriched in brain). Again, Rheb was discovered to act downstream of TSC2 via genetic epistasis analysis in Drosophila (Saucedo et al., 2003; Stocker et al., 2003) . Independent work in mammalian cells showed that GTP-bound Rheb strongly stimulates mTOR activity both in vitro and in vivo, and TSC2 increases the intrinsic rate of GTP hydrolysis on Rheb to inactivate it (Garami et al., 2003; Inoki et al., 2003a; Tee et al., 2003b) . For several years, an active search for an intermediary molecule between Rheb and mTOR yielded little or no result, indicating that Rheb might be the direct upstream regulator of mTOR in vivo. Indeed, recent work in S. pombe has shown that only a hyperactive, GTP-bound mutant of Rheb (but not wild-type Rheb) can form a complex with TOR2 (Urano et al., 2005) . It has also been shown in HEK293 cells that Rheb binds mTOR and mLST8 directly both in vitro and in vivo. Puzzlingly, although mutants of Rheb that are defective in GTP binding cannot activate mTOR, the binding of Rheb to mTOR does not require Rheb to be bound to a guanine nucleotide in any way (Long et al., 2005a, b) . Reconciling the two observations that GTP is required for Rheb binding to TOR2 in S. pombe but not to mTOR in mammalian cells is difficult, and future studies are needed to clarify the mechanism of Rheb in mTOR activation.
The identity of the putative guanine nucleotide exchange factor (GEF) or guanine nucleotide dissociation factor (GDI) for Rheb also remains a mystery. One possibility is that a GEF or GDI for Rheb does not exist, owing to Rheb's extremely low basal GTPase activity (Li et al., 2004) . Alternately, it is possible that no single GEF exists, but rather several GEFs or GDIs might overlappingly act on Rheb. Yet another unanswered question is how Rheb affects mTORC2 activity. As GTP-bound Rheb specifically binds to TOR2 in S. pombe, it is possible that Rheb regulates mTORC2 in mammalian cells, but whether Rheb's effect on mTORC2 is positive or negative is unknown. Thus, the TSC1/2 complex, by increasing GTP hydrolysis on Rheb, leads to decreased mTOR activity ( Figure 1 ).
Insulin/PI3K signaling and mTOR
The TSC1/2 complex has been shown to receive inputs from a diverse set of signal-transduction pathways, and the list of putative binding partners for TSC1 and TSC2 is fairly long . Predictably, many of the molecules that have been shown to bind or regulate the TSC1/2 complex can also regulate mTOR. The most studied and significant example of this phenomenon involves the serine/threonine kinase Akt. Akt is activated downstream of growth factors such as insulin or epidermal growth factor (EGF), by both phosphorylation and by the lipid products of phosphatidylinositol 3-kinase (PI3K). Once activated, Akt then phosphorylates a variety of prosurvival and progrowth targets, and work performed in cultured mammalian cells has shown that Akt directly phosphorylates and reduces the activity of TSC2 (Gao et al., 2002; Inoki et al., 2002; Potter et al., 2002) . By doing so, Akt increases signaling through Rheb and mTOR.
Akt is a particularly potent oncogene, and although it phosphorylates an array of substrates ostensibly unrelated to TSC1/2 and mTOR, Akt-driven tumorgenesis is remarkably sensitive to mTOR inhibition. One particularly dramatic murine study showed that Aktdriven prostate intraepithelial neoplasia is completely reversible by the mTOR inhibitor RAD001 (Majumder et al., 2004) . This overall concept -that mTOR represents a primary target of Akt in cell growth and proliferation -was foreshadowed by genetic studies of the Drosophila TOR pathway. Deletion of tsc1 or tsc2 in fly organs such as the eye leads to the characteristic phenotype of overgrown cells and organs, and epistasis analysis reveals that the overgrowth phenotype caused by absence of tsc1 or tsc2 is dominant to the decreased cell and organ size phenotype associated with akt deficiency (Potter et al., 2001) . Moreover, overexpression of the phosphoinositide phosphatase pten (phosphatase and tensin homolog deleted on chromosome 10) -which downregulates Akt activity by decreasing D3 phosphoinositide concentration -causes an increased cell size phenotype that is suppressed by the loss of tsc1 or tsc2 (Potter et al., 2001) . Consistent with these data, loss of Drosophila TOR (Zhang et al., 2000) or S6K (Montagne et al., 1999) also causes a reduced cell size phenotype, which is dominant to the increased cell size phenotype that would be expected from pten loss.
What makes the PTEN/Akt/mTOR story of such great importance is that PTEN mutations in humans (and the subsequent dysregulation of Akt) are associated with a subset of benign tumor syndromes as well as a variety of malignancies (Eng, 2003) . The rate of mutation of PTEN in certain malignancies such as prostate cancer can be as high as 50%, and murine models of PTEN-driven neoplasias have been shown to be remarkably sensitive to mTOR inhibition (Neshat et al., 2001; Podsypanina et al., 2001; Majumder and Sellers, 2005) . Akt and/or PTEN-driven mTOR regulation has also been shown to be pathophysiologically relevant in the context of several other systems, including skeletal muscle hypertrophy (Bodine et al., 2001) , hematologic disorders (Shi et al., 2002; Wendel et al., 2004) , and cardiac muscle hypertrophy (Shioi et al., 2002 (Shioi et al., , 2003 .
Negative and positive feedback
In normal cells the activation of Akt is restrained by critical negative feedback mechanisms. The existence of such negative feedback loops was predicted by the observation that insulin-or growth factor-stimulated activation of Akt tapers off after prolonged treatment (Haruta et al., 2000) . Although PTEN is a key downregulator of Akt signals and an obvious candidate for negative feedback, it is not the molecule directly responsible for decreased Akt activity over time. Instead, several groups have unexpectedly shown that increased activity of the mTOR target S6K (owing to overexpressed Rheb or loss of function of the TSC1/2 complex) reduces expression of insulin receptor substrate (IRS-1), the intermediary molecule between the insulin receptor and PI3K. Furthermore, S6K was shown to directly phosphorylate IRS proteins on several inhibitory sites (Haruta et al., 2000; Harrington et al., 2004; Shah et al., 2004) . Taken together, these remarkable data suggest that chronic S6K activation eventually leads to insulin resistance, as S6K activation would eventually decrease the efficiency of signaling through the insulin receptor and IRS. Consistently, although S6K-deficient mice have a reduced b-cell mass, reduced glucose tolerance and decreased insulin secretion, they are able to maintain normal fasting blood glucose levels owing to insulin hypersensitivity resulting from loss of S6K-mediated negative feedback (Um et al., 2004) . Negative feedback mechanisms may also begin to explain why tumors lacking TSC1/2 complex function usually remain benign, rather than progress to malignancy.
Elegant murine experiments using mice heterozygous for PTEN and/or TSC2 have shown that negative feedbackmediated reduction of the PTEN/PI3K/Akt pathway in tumors lacking tsc2 likely contributes to their benign nature. Correspondingly, combined tsc2 and pten heterozygous mice display a severe, synergistic phenotype (Ma et al., 2005b; Manning et al., 2005) .
The regulation of Akt itself is also of great interest in the context of mTOR signaling. Akt is first activated by the lipid products of PI3-kinase (D3 phosphoinositides), and subsequently by direct phosphorylation on two sites, T308 and S473. The kinase that phosphorylates Akt on T308 is 3-phosphoinositide-dependent protein kinase-1 (PDK1), an AGC kinase that is recruited by D3 phosphoinositides. The identity of the PDK2 that phosphorylates S473 in vivo has been debated for over 10 years, and it has variously been suggested to be Akt itself, DNA-protein kinase (DNA-PK), integrin linked kinase (ILK), protein kinase C (PKC)a, ATM and other kinases as well (Dong and Liu, 2005) . However, a recent report by surprisingly demonstrates that the PDK2 for Akt is, in fact, mTORC2. Via a series of RNAi and overexpression experiments in Drosophila and mammalian cells, mTORC2 was shown to be required for S473 phosphorylation of Akt in vivo.
Thus, the finding that Akt is regulated by mTOR through both positive and negative feedback loops makes upstream and downstream relationships somewhat difficult to define (Figure 1 ). The significance of the relative contribution of mTORC1/S6K/IRS versus mTORC2 in the regulation of Akt remains to be seen. A key question of future investigation will be to determine how the stochiometry of the components of mTORC1 and mTORC2 contributes to their function in regulating Akt. It is known, for example, that long-term administration of rapamycin can lead to a moderate decrease in Akt activation (Edinger et al., 2003) , an observation that is at odds with the predicted role of negative feedback through S6K and IRS. Sarbassov et al. propose that long-term rapamycin treatment may sequester mTOR away from mTORC2, thereby leading to decreased S473 phosphorylation and Akt activation. Several other situations could also be imagined where stoichiometry would be significant. As mLST8 is the common component of both mTOR complexes, future investigation is required to determine whether it plays a role in regulating the ratio of mTORC1 versus mTORC2 in the cell.
Other growth regulatory pathways that affect TSC1/2 and mTOR The mitogen-activated protein kinases (MAPKs) Rsk1 and Erk have also been shown to regulate mTORC1 in response to growth stimulators such as phorbol esters and EGF, respectively (Roux et al., 2004; Ma et al., 2005a) . Both Rsk1 and Erk were found to phosphorylate and inhibit the function of TSC2, albeit via different mechanisms and at different phosphorylation sites. Notably, Erk-driven tumorigenesis in TSC2 þ /À tumor cells was shown to be blocked by an Erknonphosphorylatable TSC2 mutant, but reintroduction of wild-type TSC2 was ineffective in suppressing tumor growth (Ma et al., 2005a) . It is also worthwhile to note that agonists which activate PKC such as phorbol 12-myristate 13-acetate can also regulate mTOR via PKCmediated activation of Ras and Raf (Iijima et al., 2002; Tee et al., 2003a) . Collectively, these findings place the Ras/MAPK pathway -independently of Ras's ability to activate PI3K -upstream of the TSC1/2 complex. The findings are of added significance since NF1, the gene mutated in the neurofibromatosis type 1 hamartoma tumor syndrome, codes for a Ras GAP that has been shown to regulate TSC2 and mTOR through the Ras/ MAPK signal-transduction cascade .
Regulation of the mTOR pathway by the tumor suppressor gene p53 has also been an active area of investigation. The p53 protein is upregulated and protected from degradation in response to DNA damage and other agonists, functioning in both apoptosis initiation and cell cycle exit. Recently, it has been shown that p53 negatively regulates mTOR, as measured by S6K and 4EBP1 activity (Horton et al., 2002; Constantinou and Clemens, 2005; Feng et al., 2005) . The suggested mechanism is that p53 activates TSC1/2 and mTOR in response to energy stress through the 5 0 adenosine monophosphate-activated protein kinase (AMPK) (see below for a discussion of AMPK) (Feng et al., 2005) . However, two other seemingly conflicting possibilities have also been suggested, as it has also been proposed that p53 acts parallel to mTOR (Jones et al., 2005) , and downstream of mTOR as one of its substrates (Castedo et al., 2002; Tirado et al., 2003) . Given the complexity of p53 regulation in different cell types, at different stages of the cell cycle, and in response to different agonists, considerable future investigation is required to determine its true physiological role with respect to mTOR.
Many other growth regulatory proteins interact with the TSC1/2 complex and thereby regulate mTOR. Several molecules critical for cell cycle progression have recently been shown to interact with TSC1 or TSC2 in mammalian cells, including: D-type cyclins (Zacharek et al., 2005) , polo-like kinase 1 (Astrinidis et al., 2006) and the cyclin-dependent kinase inhibitor p27 , These findings are not surprising; well before the mammalian homolog of TOR was discovered, it was surmised that whatever molecule rapamycin targeted must have a significant effect on cell cycle progression, given the profound effects of rapamycin treatment in T lymphocytes and in yeast (Sabers et al., 1995) . Other growth regulatory proteins that have been shown to affect mTOR via TSC1/2 include the SMAD (mothers against decapentaplegic) proteins (Birchenall-Roberts et al., 2004) , the focal adhesion kinase interacting protein FIP200 (Gan et al., 2005) , the estrogen receptor (Finlay et al., 2004) and many more than space will allow us to mention in detail. As mouse models have been dramatically successful in demonstrating the relevance of insulinand Akt-mediated mTOR activation, future study of the many biochemical observations listed above will require similar experiments to be performed.
mTOR, nutrients and cellular energy
Along with the maintenance of osmotic neutrality, translation and ribosome biogenesis are among the most energetically intensive processes that a cell must perform (Schmidt, 1999) . Therefore, it is not unexpected that these processes must be closely regulated during times of low ATP (adenosine triphosphate) or nutrient (amino acid) availability. It has been known for several years that culturing cells under low nutrient conditions leads to a strong reduction in S6K and 4EBP1 phosphorylation, a result that is satisfyingly consistent with mTOR's role in translation regulation (Hara et al., 1998) . Nutrient sensation by TOR is highly conserved in all eukaryotic organisms tested, including plants, yeast and the fly (reviewed by Shamji et al., 2003; Fingar and Blenis, 2004; Hay and Sonenberg, 2004; Menand et al., 2004; Proud, 2004b; Avruch et al., 2005) . TOR has even been shown to be the sensor responsible for turning on egg development in the malarial mosquito after it consumes its nutrient-laden blood meal (Hansen et al., 2004) . However, despite the strong conservation of TOR as a nutrient sensor, there is a significant lack of agreement on a unifying mechanism to explain how TOR is regulated in response to nutrients.
For instance, it has been proposed that nutrients activate mTOR in both a TSC1/2-dependent (Gao et al., 2002) and TSC1/2-independent (Smith et al., 2005) fashion. Some studies suggest that Rheb is integral to nutrient sensing, as overexpressed Rheb has been shown to override nutrient deprivation signals to mTOR (Inoki et al., 2003a) , and nutrient deprivation signals may decrease Rheb binding to mTOR (Long et al., 2005b) . Other work implies that Rheb may not be involved at all, but rather that nutrient poor conditions lead to increased Raptor/mTOR binding and subsequently decreased mTORC1 activity (Kim et al., 2002) . Other studies point to hVps34, a class III PI3K (unrelated to the PI3K that is upstream of Akt), as a critical factor in the regulation of TOR by nutrients (Byfield et al., 2005; Nobukuni et al., 2005) . hVps34 was shown to be activated by the presence of amino acids and is inhibited by AMPK, but the mechanism by which it regulates mTOR is unknown. The hVps34 data are consistent with nutrient sensation acting through a pathway parallel to the TSC/Rheb signaling axis, but are directly in contrast to the evidence that TSC1/2 is in fact required for nutrient sensation. Thus, it is clear that the mechanism of nutrient sensation by mTOR requires considerable future investigation.
Study of how cellular energy regulates mTOR has recently made significant progress. Culturing mammalian cells under low glucose conditions or treating them with the non-hydrolysable glucose analog 2-deoxyglucose (2-DG), depletes the energy of the cell and causes a concomitant decrease in the activity of mTOR (Dennis et al., 2001) . One mechanism proposed to account for decreased mTOR activity is that mTOR itself senses energy depletion and decreases its activation accordingly (Dennis et al., 2001) . However, this mechanism may only account for conditions of severe energy stress, as the ATP depletion required to achieve mTOR inhibition is below the normal range of physiological ATP levels (Inoki et al., 2003b) .
A more plausible mechanism to explain how energy levels couple to the regulation of mTOR is via activation of AMPK. AMPK is activated allosterically by AMP as well as by phosphorylation on its activation loop threonine, T172. A high amount of AMP in the cell reflects a low energy status, and the AMP/ATP ratio in the cell is much higher during energy stress. Studies which first implicated AMPK in the regulation of mTOR showed that pharmacological activation of AMPK by the ribonucleoside AMP analog AICAR caused a dramatic reduction of S6K and 4EBP1 activity; and culturing cells in low glucose or treating cells with 2-DG had the same effect of reducing mTOR activation (Bolster et al., 2002; Krause et al., 2002; Kimura et al., 2003) . In response to low energy, AMPK phosphorylates several targets to enhance catabolism and suppress anabolism, and it was recently shown that the mechanism by which it regulates mTOR is via direct phosphorylation of TSC2 (Inoki et al., 2003b) . Phosphorylation of TSC2 by AMPK is required for translation regulation and cell size control in response to energy deprivation, and when AMPK phosphorylation sites are absent on TSC2, energy depletion has little or no effect on mTOR activation. Furthermore, cells either null for TSC2 or those that express mutants of TSC2 that cannot be phosphorylated by AMPK undergo quick apoptosis under energy starvation conditions (Inoki et al., 2003b) . Thus, energy depletion is sensed by AMPK and relayed to mTOR through the TSC1/2 complex (Figure 2) .
It is critical to note that full activation of AMPK is only achieved after phosphorylation on its activation loop by LKB1, a serine/threonine kinase that exists in a multi-protein complex with two adaptor molecules, STRAD and MO25 (Baas et al., 2003; Woods et al., 2003) . By phosphorylating AMPK, LKB1 also significantly affects signaling through mTOR; and LKB1 kinase activity is required for AMPK activation, as AMPK activity in response to low energy conditions is deficient in LKB1 null cells (Corradetti et al., 2004) . It is especially significant that LKB1 is upstream of mTOR, as it is mutated in Peutz-Jeghers syndrome, an autosomal dominant hamartoma syndrome that shares certain clinical similarities with TSC . Moreover, LKB1 heterozygous mice, which phenocopy human Peutz-Jeghers syndrome, display elevated S6K phosphorylation in hamartomatous tissues (Shaw et al., 2004) . It has also recently been shown that mice with a tissue-specific deficiency of LKB1 in the liver display certain diabetic phenotypes such as hyperglycemia and increased lipogenic gene expression (Shaw et al., 2005) . This is not surprising, as the commonly used antidiabetic drug metformin has been shown to directly activate AMPK (Zhou et al., 2001) and requires LKB1 to function (Shaw et al., 2005) . Finally, LKB1 has also recently been shown to phosphorylate 13 other kinases that are phylogenetically related to AMPK (Lizcano et al., 2004) . The relevance of these kinases in the regulation of mTOR has not been demonstrated, but it is possible that some of these kinases may also regulate mTOR via phosphorylation of TSC2.
Regulation of mTOR by cellular stressors
The list of cellular stressors that have been shown to regulate mTOR in cell culture systems is staggering and includes hypoxia, osmotic stress, DNA damage, ultraviolet (UV) and ionizing radiation, viral infection and reactive oxygen species (ROS) (Proud, 2004a) . As is the case for energy or nutrient metabolism, most stressors suppress translation, as translation is an energy intensive metabolic process that must be downregulated during times of cellular crisis. Many stressors also eventually lead to ATP depletion and thereby activate AMPK (Hardie, 2004) . However, although AMPK activation is one mechanism by which mTOR could be suppressed by stress, several other mechanisms have been proposed to explain how mTOR is regulated during shorter time periods, when ATP levels may still be in the normal range. Below we mention stress conditions that have been linked to the mTOR signaling network and have not been extensively covered in other reviews.
Hypoxia
Under conditions of low oxygen (hypoxia), transcription and translation of many stress responsive genes is increased. One such gene, the hypoxia inducible factor (HIF-1), is a critical transcription factor that regulates many genes directly involved in angiogenesis, including the vascular endothelial growth factor. Von-Hippel Lindau disease, a syndrome of abnormal hypervascularization, is caused by mutations in VHL, a gene that promotes ubiquitination and degradation of HIF-1. Mouse models of VHL null kidney cancer (which have pathologically elevated levels of HIF-1) and mouse models of Akt-driven prostate cancer both display transcription profiles consistent with high HIF-1 activity, and both tumor types are dramatically sensitive to inhibitors of mTOR (Majumder et al., 2004; Thomas et al., 2006) . Furthermore, in osteoblasts, prostate cancer cells and TSC null fibroblasts, mTOR has been shown to increase HIF-1 translation (but not transcription) in a rapamycin reversible manner (Hudson et al., 2002; Brugarolas et al., 2003) . Taken together, these results suggest a role for mTOR as an upstream regulator of responses to hypoxia (Figure 2) . Figure 2 Energy and cellular stress signaling couple to mTOR. Cellular stressors that initiate signal transduction are shown in red text. Under low energy conditions, AMPK is activated by both AMP and its upstream kinase, LKB1. AMPK then phosphorylates and activates TSC2 in order to downregulate mTOR activity. Hypoxia is shown playing the dual role of both activating HIF-1 translation in an mTORC1-dependent manner, as well as downregulating mTORC1 activity through the action of RTP801. RTP801 is also inducted in response to DNA damage, glucocorticoids and other stressors.
Somewhat paradoxically, it was also recently shown that mTOR acts downstream of hypoxia, as culturing several cell types under hypoxic conditions can induce a robust inhibition of mTOR activity. This effect is independent of AMPK activation and the energy status of the cell and is dominant to activators of mTOR such as insulin, amino acids, phorbol esters and serum (Arsham et al., 2003) ; but it is dependent on an intact TSC1/2 complex, as hypoxic treatment of TSC1 or TSC2 null mouse embryonic fibroblasts (MEFs) fails to have any effect on S6K phosphorylation (Brugarolas et al., 2004) . One mechanism proposed to account for this result involves a protein called RTP801 (also known as Redd1). RTP801 is a small, 34 kDa protein that displays little homology to known functional domains other than a coiled-coil domain in its C-terminus (Ellisen et al., 2002) . RTP801 is the human orthologue of the Drosophila genes Scylla and Charybdis, which were identified in a screen for proteins that suppress a PDK1/Akt-driven 'bigeye' cell size phenotype . Scylla and Charybdis are induced under hypoxic conditions and were shown via epistasis anaylsis to act between Akt and the TSC1/2 complex in suppressing cell growth . Subsequently, the human orthologues of Scylla and Charybdis, RTP801 and RTP801L, were shown to negatively regulate mTOR downstream of Akt and upstream of the TSC1/2 complex (Figure 2) (Brugarolas et al., 2004; Corradetti et al., 2005) . RTP801 is transcriptionally induced by HIF-1 under conditions of hypoxia (Shoshani et al., 2002) and is required for the effect of hypoxia on mTOR, as RTP801 null MEFs are defective in hypoxia-mediated inhibition of S6K (Brugarolas et al., 2004) . However, the detailed mechanism by which RTP801 mediates mTOR inhibition in response to HIF-1 remains a mystery.
The two observations -that mTOR is both regulated by HIF-1 through RTP801 and that mTOR affects HIF-1 expression itself -seem to be at odds with each other. One explanation that begins to reconcile these observations is that rapamycin treatment only causes a partial (less than 50%) reduction in HIF-1 expression, indicating mTOR-independent pathways also affect HIF-1 expression (Brugarolas et al., 2003) . It is also possible that hypoxia-mediated inhibition of mTOR by RTP801 occurs only at shorter time points, whereas HIF-1 upregulation by mTOR only occurs after an extended period of time. Notably, RTP801 has also been shown to be induced in response to energy stress (Sofer et al., 2005) , arsenic and hydrogen peroxide , glucocorticoid treatment (Wang et al., 2003b) , DNA damaging agents (Ellisen et al., 2002) and other stressors. Future investigation is required to determine the significance of RTP801 in relaying these additional stresses to mTOR. It will also be interesting to determine whether RTP801 possesses catalytic activity, whether it serves as an adaptor protein, or whether it has some other, mechanism of action.
Osmotic stress
Osmotic stress is a general term that refers to a change in the concentration of dissolved molecules in the exterior environment of the cell. The term 'osmotic stress' usually refers to hyperosmotic stress, or the condition in which the concentration of solutes outside the cell is higher than the concentration inside the cell. At low-tomoderate concentrations, addition of an osmolite such as sorbitol or mannitol to the cell culture medium can cause transcription or translation changes, alterations in metabolism and cellular shrinkage. At higher concentrations osmotic shock can lead to apoptotic or necrotic cell death.
It has been known for decades that hypertonic stress induced by sorbitol treatment of cells reversibly decreases the phosphorylation of S6K, as well as the overall translational output of the cell (Saborio et al., 1974; Kruppa and Clemens, 1984) , but mechanisms to explain how this occurs have only recently been proposed. One suggested mechanism is that osmotic stress induced by sorbitol treatment causes a rapid and reversible disintegration of the mitochondrial proton gradient. This reduction in mitochondrial function is postulated to be linked with downregulation of mTOR activity, as mTOR has been shown to associate with the mitochondrial outer membrane (Desai et al., 2002) . These results could imply that mTOR itself senses changes in osmotic stress, perhaps via the mitochondrial membrane potential or through mitochondrial proteins.
Another mechanism suggests that the reduction of mTOR activity by sorbitol may be due to the activation of a phosphatase, as the phosphatase inhibitor calyculin A (but not other phosphatase inhibitors) was shown to prevent osmotic stress-induced inhibition of S6K (Parrott and Templeton, 1999) . Consistent with these data, osmotic stress-mediated dephosphorylation of S6K is independent of TSC2 (Smith et al., 2005) , independent of Rheb (Inoki et al., 2003a) and dominant to Akt overexpression (Parrott and Templeton, 1999) . The reduction in mTOR activity in response to sorbitol was also shown to be independent of p38 MAPK, a kinase that is activated by a variety of stress stimuli including osmotic stress and UV radiation (Parrott and Templeton, 1999; Patel et al., 2002) . This kinase was important to exclude, not only because of p38's central role as a stress-inducted kinase, but also because p38 phosphorylates and activates MK2 (also known as MAPKAPK2); and MK2 is directly responsible for the phosphorylation of TSC2 on S1210 . However no physiological linkage between sorbitolmediated inhibition of mTOR and TSC2 phosphorylation on S1210 has been found.
It also bears mentioning that experiments performed in the plant Arabidopsis showed that osmotic stress induced by mannitol dramatically reduced S6K phosphorylation. This osmotic response was reversible by overexpression of Raptor, and interestingly, transgenic plants expressing high levels of S6K were rendered hyperresponsive to osmotic stress-mediated cell shrinkage (Mahfouz et al., 2006) . Although it is certain that these results demonstrate an impressive evolutionary conservation of components of the mTOR signaling network, it is not clear whether in higher eukaryotes Raptor plays a role in osmotic stress sensation, or whether S6K overexpression can induce such a dramatic response to osmotic stress. It should also be mentioned that osmotic stress induced by high salt concentration has recently been shown to inhibit mTOR (Naegele and Morley, 2004) , but whether salt-induced osmotic stress acts via the same mechanism as sorbitol-induced stress is unclear. In the future it will be interesting to determine whether a phosphatase is responsible for osmotic stressinduced S6K dephosphorylation, whether some unknown component of the pathway relays osmotic stress sensation to mTOR, or whether mTOR senses osmotic stress by itself.
ROS
All aerobic organisms produce ROS as a byproduct of respiration. ROS molecules such as hydroxyl radicals, superoxide anions and singlet oxygen are extremely reactive; and unless they are detoxified by antioxidant enzymes, they can cause irreversible damage to intracellular molecules such as nucleic acids and proteins. Although low levels of ROS are normally produced by the mitochondria and are usually detoxified quickly, an excessive accumulation of ROS -caused by UV or ionizing irradiation, chemical insult, or an aging cellmay trigger a diverse range of cellular responses, including cell growth, proliferation, or apoptosis. Complicating matters further, the effect of oxidizing agents seems to vary with the cell type tested, the dose and type of the oxidizing agent and the time of treatment (Boonstra and Post, 2004; Temple et al., 2005) . Consistent with these observations, oxidizing agents have been shown to affect the mTOR pathway both positively and negatively.
For example, short-term hydrogen peroxide treatment (a strong oxidizing agent) has been shown to profoundly inhibit translation, as well as the phosphorylation of S6K and 4EBP1 in CHO K1 (Chinese hamster ovary) cells, but nearly identical treatment of TSC2 À/À MEFs led to an increase in S6K phosphorylation (Patel et al., 2002; Smith et al., 2005) . The response of TSC2 À/À MEFs to peroxide is somewhat puzzling, as basal ROS levels are significantly higher in TSC2 À/À cells, as a result of increased mitochondrial function (Finlay et al., 2005) . Moreover, peroxide or arsenite treatment of JB6 cells (a mouse epidermal cell type) has been shown to lead to an increase in S6K and 4EBP1 activation (Bae et al., 1999; Huang et al., 2002; Jung et al., 2003) . In addition, UV irradiation (which increases the amount of ROS in the cell) of HEK293 cells (Parrott and Templeton, 1999) and JB6 cells has been shown to increase the phosphorylation of S6K. It should be noted that the oxidizing agents arsenic and hydrogen peroxide have also been shown to induce the transcription of RTP801 , although the inhibition of mTOR by RTP801 occurs at a much later time point than the activation of mTOR by peroxide and arsenic.
It has also been reported in HEK293 cells that S6K phosphorylation is increased in response to thiol oxidizing agents that specifically target disulfide bonds. This effect is dominant to mTOR inhibiting conditions, such as nutrient or energy deprivation, but not to inhibitors of PI3K and mTOR. Thiol oxidation also induces destabilization of the Raptor-mTOR interaction , consistent with previous data that showed the Raptor-mTOR interaction is stabilized by mTOR inhibiting agents (Kim et al., 2002) . Recent work in yeast suggests that mTOR itself may sense changes in the thiol reduction status of the cell, as the FATC domain of TOR1 possesses a novel disulfide-bonded structural motif that is changed dramatically when reduced (Dames et al., 2005) . Thus, a considerable amount of future work is required to determine the physiological relevance of ROS in the regulation of mTOR.
Viruses and mTOR
The cell's response to the stress of viral infection can be either adaptive or maladaptive. Viral proteins, for instance, can hijack the cell growth apparatus (a maladaptive event for the cell) in order to produce more viral particles and thereby increase infection. This phenomenon is well illustrated by the DNA tumor viruses, which possess proteins that mimic or bind to cellular oncogenes and tumor suppressor genes in order to promote cell growth (O'Shea, 2005) . In contrast, certain viral infection conditions have also been shown to lead to an adaptive response, such as enhancement of apoptotic cell death or the upregulation of autophagy (to degrade intracellular pathogens). Study of the role of mTOR in these processes is relatively new, but both adaptive and maladaptive responses have been observed. Upregulation of mTOR activity is associated with increased cellular synthesis of viral particles and increased cell growth. Downregulation of mTOR activity is associated with increased autophagy, reduced cell growth and protection from further infection. Here we discuss adenoviruses and cytomegaloviruses, two types of viruses that have been well studied with respect to their positive regulation of the mTOR signaling network.
Adenoviruses are double-stranded DNA viruses that have been extensively characterized with respect to their effect on cellular signal transduction, and they are responsible for a wide range of common respiratory infections. Recently it has been shown that adenoviral infection of airway epithelial cells -a typical cell type targeted by adenoviruses in vivo -causes dramatic increases in the activation of mTOR, even under low nutrient conditions; and significantly, mTOR activation is required for infected cells to efficiently progress to S phase (O'Shea et al., 2005a) . The activation of mTOR was shown to be caused by two adenovirus-encoded proteins. The first protein, E4-ORF1, is both necessary and sufficient to activate PI3K by adenovirus infection. However, E4-ORF1 is not required to activate mTOR, as E4-ORF1-deleted adenoviruses are still able to partially induce S6K (Frese et al., 2003; O'Shea et al., 2005a) . A second protein, E4-ORF4, was shown to be essential for mTOR activation by adenoviral infection. Interestingly, E4-ORF4 does not affect Rheb GTP levels, but its protein phosphatase 2A binding domain is required for S6K activation (O'Shea et al., 2005a) . Taken together, these data indicate that adenoviruses have evolved mechanisms to commandeer control of the mTOR pathway, and such control is required for efficient adenovirus propagation. The results also have implications for adenoviral gene therapy research. For instance, engineered adenoviruses that are defective in their activation of essential growth regulatory genes such as retinoblastoma protein (pRb) can only replicate in -and thereby kill -tumor cells with a hyperactive pRb pathway, potentially sparing cells with normal pRb activity (Johnson et al., 2002) . One could imagine the creation of similar E4-ORF1 and E4-ORF4 adenoviral mutants that are deficient in activation of mTOR, in order to specifically treat tumors with increased mTOR activity (O'Shea et al., 2005b) . Paradoxically, it should be noted that it has also been shown that the mTOR inhibitor RAD001 increases the efficacy of replicating adenoviruses used for colon cancer ablation (Homicsko et al., 2005) .
Human cytomegalovius (HCMV) is an extremely common herpesvirus family member that is usually of little clinical consequence in healthy individuals. However, HCMV infection in immunocompromised patients such as transplant recipients and acquired immunodeficiency syndrome patients can be a significant cause of morbidity and mortality. HCMV enters cells by binding to the epidermal growth factor receptor (EGFR). Upon binding, HCMV is internalized and initiates typical EGFR signaling, including the activation of PI3K and Akt (Wang et al., 2003a) . Subsequently, the phosphorylation of both S6K (Johnson et al., 2001; Andreoni et al., 2002) and 4EBP1 (Kudchodkar et al., 2004 ) is strongly induced, although one group finds that 4EBP1 is induced independently of PI3K (Kudchodkar et al., 2004) . PI3K/Akt activation is especially significant as HCMV replication and viral gene expression is significantly reduced by the PI3K inhibitor LY294002 (Johnson et al., 2001) . The importance of mTOR inhibition in preventing HCMV pathogenesis was compellingly shown in the context of a double-blind clinical study of heart transplant recipients. Patients that received the mTOR inhibitor RAD001 and cyclosporine for immunosuppression had a significantly lower incidence of HCMV infection and vasculopathy compared to patients that received cyclosporine and azathioprine (Eisen et al., 2003) . Similar reductions in HCMV infection by mTOR inhibition were found in liver and kidney transplant patients (reviewed by Ponticelli (2004) ). These data indicate that mTOR may be essential for HCMV infection and propagation in vivo, and suggest that the use of mTOR inhibitors for immunosuppression may be preferable to other drugs, at least from the perspective of reducing HCMV infection. As the biochemical data to support the observations made in the clinic are still somewhat lacking, it will be critical to more extensively determine the mechanism of how mTOR inhibition prevents the pathogenic effects of HCMV.
Conclusions
Although mTOR was discovered over 10 years ago and rapamycin has been used in the clinic for an even longer time, there are still many unanswered questions regarding the regulation of the mTOR signaling network. It is clear that mTOR is affected by an enormous variety of cellular stressors and cell growth regulators, leading to the question: How many undiscovered links still exist between mTOR and other agonists, stresses and cell growth signaling pathways? The best piece of evidence that supports greater complexity in upstream signaling is the many agonists that have already been shown to impinge upon mTOR. In addition, mTOR knockout mice are embryonic lethal as early as E5 and have defects in embryonic stem cell growth (Gangloff et al., 2004; Murakami et al., 2004) , implying the mTOR plays a central role in primordial development. The fact that mTOR may control a low percentage (perhaps 15%) of the translational output of the cell (Jefferies et al., 1994) has often been cited as a reason why mTOR is not a nexus for translation regulation. Although this may be so, any protein that nonredundantly controls 15% of mRNAs must presumably be regulated by pathways that require these mRNAs to function. Little is known about regulation of the mTOR signaling network by agonists such as Wnt, hedgehog and notch, yet the study of these three signaling pathways represent a significant portion of current research in developmental biology and oncogenesis. Future investigation should be aimed at determining the relationships between such types of agonists and mTOR. The fact that mTOR is dysregulated in many human diseases and that rapamycin may be therapeutically useful to treat them highlights the necessity of understanding how mTOR integrates numerous upstream signals to control the cell.
